State Street Corp Oncternal Therapeutics, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$0.83 - $17.8 $37,433 - $802,780	-45,100 Reduced 21.84%	161,401 $144,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $460,865 - $1.03 Million	-658,380 Reduced 76.12%	206,501 $229,000
Q1 2022 May 16, 2022	BUY	$1.37 - $2.43 $7,280 - $12,913	5,314 Added 0.62%	864,881 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $117,881 - $227,972	51,930 Added 6.43%	859,567 $1.95 Million
Q3 2021 Nov 15, 2021	BUY	$3.37 - $4.76 $257,623 - $363,882	76,446 Added 10.45%	807,637 $3.37 Million
Q2 2021 Aug 16, 2021	BUY	$4.75 - $9.39 $3.38 Million - $6.68 Million	711,877 Added 3685.81%	731,191 $3.47 Million
Q1 2021 May 17, 2021	BUY	$4.59 - $9.04 $6,426 - $12,655	1,400 Added 7.82%	19,314 $161,000
Q3 2020 Nov 10, 2020	SELL	$1.7 - $3.28 $5,973 - $11,525	-3,514 Reduced 16.4%	17,914 $30,000
Q2 2020 Aug 14, 2020	SELL	$2.43 - $3.23 $4,546 - $6,043	-1,871 Reduced 8.03%	21,428 $61,000
Q1 2020 May 11, 2020	BUY	$2.49 - $4.39 $58,014 - $102,282	23,299 New	23,299 $68,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.